BO-112联合帕博利珠单抗治疗抗PD-1耐药晚期黑色素瘤:II期临床试验SPOTLIGHT-203
该II期试验纳入42例抗PD-1耐药晚期黑色素瘤患者,给予瘤内注射BO-112联合静脉帕博利珠单抗治疗。可评估疗效的40例患者客观缓解率为25%(完全缓解10%、部分缓解15%),达到主要终点;中位无进展生存期3.7个月,24个月总生存率54%,≥3-4级不良事件16例(38.1%),无治疗相关死亡。
要点
- 抗PD-1耐药黑色素瘤患者中,BO-112联合帕博利珠单抗的客观缓解率为25%(40例可评估患者)。
- 42例意向治疗人群中,中位无进展生存期3.7个月(95%CI 2.2-9.2),24个月总生存率54%。
- ≥3-4级不良事件16例(38.1%),其中药物相关4例(9.5%),无治疗相关死亡。
核心结论
- 该临床试验达到主要终点(客观缓解率),BO-112联合帕博利珠单抗可能成为逆转黑色素瘤患者抗PD-1耐药的一种策略。
- 无进展生存期结果与抗PD-1耐药情境下其他临床试验一致,总生存数据有前景。
研究设计与样本
- II期临床试验SPOTLIGHT-203(ClinicalTrials.gov注册号NCT04570332),纳入42例抗PD-1耐药晚期黑色素瘤患者。
- 治疗方案为瘤内注射BO-112每周一次共7周,之后每3周一次(每次最多2 mg,最多8个病灶),联合静脉帕博利珠单抗200 mg每3周一次,直至疾病进展、不可接受毒性、死亡或最多1年。
- 主要终点为独立中心放射学评审按RECIST 1.1评估的客观缓解率,在改良意向治疗人群(mITT,可评估疗效患者)中分析,阳性阈值20%。
- 关键次要终点为无进展生存期、总生存期、缓解持续时间和安全性。
主要发现
- 改良意向治疗人群40例,客观缓解率25%,其中完全缓解10%、部分缓解15%、疾病稳定40%,中位缓解持续时间未达到(95%CI 8.3至未达到)。
- 意向治疗人群42例,中位无进展生存期3.7个月(95%CI 2.2至9.2),中位总生存期未达到(95%CI 9.9至未达到),24个月时54%患者存活。
- 16例(38.1%)发生≥3-4级不良事件,其中4例(9.5%)为药物相关,无治疗相关死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with anti-PD-1-resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered intratumorally has showed in patients with solid tumors potential to revert this resistance. We report efficacy and safety of the phase II clinical trial of intratumoral BO-112 plus intravenous pembrolizumab for patients with anti-PD-1-resistant MEL (ClinicalTrials.gov identifier: NCT04570332). METHODS: Forty-two patients were treated with intratumoral BO-112 once every week for 7 weeks and then once every 3 weeks (up to 2 mg and up to eight lesions per treatment) combined with 200 mg pembrolizumab once every 3 weeks until progressive disease, unacceptable toxicity, death, or up to 1 year. Primary end point was RECIST 1.1 objective response rate (ORR) by independent central radiology review in modified intention-to-treat population (mITT; patients evaluable for response) with 20% ORR positivity threshold. Secondary key end points were progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety. RESULTS: For mITT, there were 40 patients and the ORR was 25%, with 10% complete, 15% partial, and 40% stable disease, with nonachieved (NA) median DOR (95% CI, 8.3 to NA). For ITT, there were 42 patients, and the median PFS and OS were 3.7 months (95% CI, 2.2 to 9.2) and NA (95% CI, 9.9 to NA), respectively, with 54% patients alive at 24 months. The combination was well tolerated: 16 patients (38.1%) experiencing ≥G3-4 adverse events, four (9.5%) drug-related, and no deaths related to treatment. CONCLUSION: The clinical trial has met its primary end point (ORR) making BO-112 with pembrolizumab a potential strategy to revert anti-PD-1 resistance in patients with MEL. PFS results are in line with other clinical trials in anti-PD-1-resistant scenario, with promising OS data.
引用
- Márquez-Rodas I, Dutriaux C, Saiag P, et al. BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. J Clin Oncol. 2025. PMID: 40577656. doi:10.1200/JCO-24-02595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。